RJA
CPRX

Raymond James & Associates’s Catalyst Pharmaceutical CPRX Stock Holding History

Raymond James & Associates’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.48M Buy
74,602
+26,231
+54% +$486K ﹤0.01% 2428
2024
Q2 		$749K Sell
48,371
-8,622
-15% -$134K ﹤0.01% 2828
2024
Q1 		$908K Buy
56,993
+6,714
+13% +$101K ﹤0.01% 2659
2023
Q4 		$845K Buy
50,279
+2,045
+4% +$28K ﹤0.01% 2619
2023
Q3 		$564K Buy
48,234
+457
+1% +$6.11K ﹤0.01% 2816
2023
Q2 		$642K Sell
47,777
-7,907
-14% -$114K ﹤0.01% 2765
2023
Q1 		$923K Buy
55,684
+13,371
+32% +$221K ﹤0.01% 2498
2022
Q4 		$787K Buy
42,313
+13,113
+45% +$202K ﹤0.01% 2570
2022
Q3 		$375K Buy
29,200
+6,876
+31% +$81.5K ﹤0.01% 3038
2022
Q2 		$156K Buy
+22,324
New +$164K ﹤0.01% 3583
2021
Q1 		– Sell
-11,726
Closed -$39K – 4014
2020
Q4 		$39K Hold
11,726
– – ﹤0.01% 3647
2020
Q3 		$35K Sell
11,726
-6,000
-34% -$23.5K ﹤0.01% 3470
2020
Q2 		$82K Sell
17,726
-1,000
-5% -$4.49K ﹤0.01% 3323
2020
Q1 		$72K Sell
18,726
-8,407
-31% -$34.5K ﹤0.01% 3271
2019
Q4 		$102K Buy
27,133
+4,126
+18% +$19.3K ﹤0.01% 3474
2019
Q3 		$122K Buy
23,007
+5,500
+31% +$29.3K ﹤0.01% 3364
2019
Q2 		$67K Buy
17,507
+4,500
+35% +$19.4K ﹤0.01% 3467
2019
Q1 		$66K Sell
13,007
-2,000
-13% -$5.88K ﹤0.01% 3450
2018
Q4 		$29K Buy
15,007
+2,500
+20% +$7.16K ﹤0.01% 3420
2018
Q3 		$47K Buy
+12,507
New +$39.2K ﹤0.01% 3497

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Raymond James & Associates's CPRX Position: Q3 2024 in Review

Raymond James & Associates increased its Catalyst Pharmaceutical (CPRX) stake by 54% in Q3 2024, buying an estimated $486K and bringing the position to 74,602 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

Raymond James & Associates first reported a position in CPRX in Q3 2018 and has held it in 20 quarters since. 316 funds tracked by Wall St. Rank hold CPRX as of Q3 2024.

  • Raymond James & Associates held 74,602 shares of Catalyst Pharmaceutical worth $1.48M as of Q3 2024.
  • Raymond James & Associates bought 26,231 Catalyst Pharmaceutical shares in Q3 2024, an estimated $486K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2428 holding.
  • Raymond James & Associates first reported a position in Catalyst Pharmaceutical in Q3 2018 and has held it in 20 quarters since.
  • 316 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.